For First-line Therapy of BRAF-mutant Melanoma, PD-1 Inhibitors May Be Preferred

Share this content:
Among patients with BRAF-mutated melanoma, BRAF/MEK and PD-1 inhibition as first-line treatment significantly improved overall survival.
Among patients with BRAF-mutated melanoma, BRAF/MEK and PD-1 inhibition as first-line treatment significantly improved overall survival.

Among patients with BRAF-mutated melanoma, BRAF/MEK and PD-1 inhibition as first-line treatment significantly improved overall survival with PD-1 inhibitors possessing the more favorable safety profile, according to a meta-analysis published in JAMA Oncology.1                      

Although multiple effective first-line systemic treatment options are available for patients with advanced BRAF-mutated melanoma, head-to-head randomized clinical trials comparing targeted therapies and immunotherapies are lacking.

To estimate the relative efficacy and safety of systemic therapeutic options for advanced, treatment-naive, BRAF-mutated melanoma, researchers conducted a systematic review and meta-analysis of phase 2 or 3 randomized controlled trials (RCTs) published up until April 29, 2016. RCTs included at least 1 intervention with a targeted (BRAF or MEK) or an immune checkpoint (cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] or programmed cell death 1 [PD-1]) inhibitor.

Analysis of 16 articles reporting 15 RCTs involving a total of 6662 patients showed that both BRAF/MEK and PD-1 inhibitors were associated with improved overall survival compared with all other treatments except anti-CTLA-4 monoclonal antibodies.

Researchers observed no significant difference in overall survival between BRAF/MEK inhibitors and PD-1 inhibitors (hazard ratio, 1.02; 95% CI, 0.72-1.45), though BRAF/MEK inhibition significantly improved progression-free survival compared with all other treatment options.

Treatment with BRAF/MEK inhibition was also associated with a higher objective response rate compared with a BRAF inhibitor alone (odds ratio [OR], 2.00; 95% CI, 1.64-2.45), but both were superior to other treatments with respect to objective response rate.

RELATED: Weighing the Benefits Against the Toxicities of Ipilimumab in Melanoma

Chemotherapy and PD-1 inhibitors were associated with the lowest risk for developing serious adverse events, and there was no significant difference in risk between the 2 strategies (OR, 1.00; 95% CI, 0.74-1.34).

The favorable efficacy and safety profile of PD-1 inhibitors support the use of PD-1 inhibitors as first-line therapy among patients with advanced BRAF-mutated melanoma when rapid response is not a priority.

Reference                  

  1. Devji T, Levine O, Neupane B, et al. Systemic therapy for previously untreated advanced BRAF-mutated melanoma. JAMA Oncology. 2016 Oct 27. doi: 10.1001/jamaoncol.2016.4877 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs